Prime Medicine

Company snapshot

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the

• 17 active pipeline program(s) linked via ClinicalTrials.gov.
• 127 US patent(s) indexed to this assignee profile.
• 17 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Prime Medicine. Not investment advice.

• Peer + 0 momentum

  HOFFMANN-LA ROCHE

  TA overlap score 40

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Nektar Therapeutics UK

  TA overlap score 31.4

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  LIGAND PHARMACEUTICALS

  TA overlap score 26.8

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

Recent activity

Latest pipeline, patent, and corporate events for Prime Medicine.

1. Jun 8, 2026 Clinical update

   Recommended treatment schedule — Phase 3

2. Jun 8, 2026 Clinical update

   PG-011 nasal spray 0.6%(twice daily) — Phase 3

3. Jun 5, 2026 Clinical update

   Pumecitinib Nasal Spray 0.3% — Phase 2

4. Jun 5, 2026 Clinical update

   Bemarituzumab — Phase 1

5. Jun 5, 2026 Clinical update

   Artificial intelligence in diagnosis — Unknown

View all clinical trial activity →

• What is Prime Medicine?

  Prime Medicine is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker PRME. Primary therapeutic focus areas include Advanced Solid Tumors, Seasonal Allergic Rhinitis, Artificial Intelligence (AI) in Diagnosis, Gastric Cancer, Gastrointestinal Ca

• Is Prime Medicine publicly traded?

  Yes. Prime Medicine is listed with ticker PRME on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Prime Medicine develop or market?

  We link 6 drug profile(s) where Prime Medicine is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/prime-medicine#company-drugs.

• What are the latest developments for Prime Medicine?

  In the last 12 months our linked public records show 17 trial program update(s) and 5 US patent grant(s) tied to this profile.

• What therapeutic areas does Prime Medicine focus on?

  Prime Medicine focuses on Advanced Solid Tumors, Seasonal Allergic Rhinitis, Artificial Intelligence (AI) in Diagnosis based on our analysis of their pipeline programs and drug development activities.